ADMA Biologics (ADMA) AGM 2026 summary

Opening remarks and agenda

• The meeting was called to order virtually, emphasizing inclusivity and broader stockholder participation.

• Legal and organizational matters were addressed to ensure the meeting was duly authorized.

• The agenda included the introduction of directors, officers, and the independent accounting firm, as well as the presentation of proposals for stockholder consideration.

Board and executive committee updates

• Directors introduced included Steven Elms, Alison Finger, Jerrold Grossman, Lawrence Guiheen, Young Kwon, and Eduardo Rene Salas.

• Officers introduced were Kaitlin Kestenberg (COO & SVP, Compliance) and Paul Terence Kohler Jr. (CFO & Treasurer).

• Representatives from KPMG LLP, the independent registered public accounting firm, were also introduced.

Shareholder proposals

• Election of Alison Finger and Eduardo Rene Salas as Class I Directors to serve until the 2029 annual meeting.

• Ratification of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.

• Advisory vote on the compensation of named executive officers (Say-on-Pay).